

(SEQ ID NO: 45), TDYYIN (SEQ ID NO: 49), NDYYIN (SEQ ID NO: 53), SDYYMY (SEQ ID NO: 57), TNYGIH (SEQ ID NO: 61), TTYGMS (SEQ ID NO: 65), XNXXXH (SEQ ID NO: 72), wherein X at position 1 is T, A, D, E, G, H, K, N, Q, R, S, V, W, or Y; X at position 3 is N, A, F, G, H, M, R, S, V, or Y; X at position 4 is W, or F; X at position 5 is M, A, D, E, F, G, L, N, Q, R, S, T, V, or W, or XXXGXS (SEQ ID NO: 344), wherein X at position 1 is T, A, D, E, G, H, K, M, N, Q, R, or S; X at position 2 is T, D, E, G, H, N, Q, or S; X at position 3 is Y, F, M, or Q; X at position 5 is M, I, L, or V;

[0013] (e) HVR-H2 comprises an amino acid sequence selected from MIHPNSGITNINE (SEQ ID NO: 42), EIYPGTIVITYYNA (SEQ ID NO: 46), WIFPGTEGIYYNE (SEQ ID NO: 50), WIFPGRIITYYNE (SEQ ID NO: 54), AISDDGTYTYPD (SEQ ID NO: 58), IIWAGGSTNYNS (SEQ ID NO: 62), WINTDS-GVPTYAD (SEQ ID NO: 66), XXHXXXXXXXXXXN (SEQ ID NO: 107), wherein X at position 1 is M or F; X at position 2 is I, L, M, or V; X at position 4 is P, A, D, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, or W; X at position 5 is N, A, D, E, F, G, H, I, K, L, M, Q, R, S, T, V, W, or Y; X at position 6 is S, A, G, T, or V; X at position 7 is G, A, or S; X at position 8 is I, A, or V; X at position 9 is T, A, D, E, G, H, I, K, L, M, N, Q, R, S, V, W, or Y; X at position 10 is N, A, M, or S; X at position 11 is I, F, G, H, K, L, M, N, Q, R, S, T, V, W, or Y; X at position 13 is E, A, D, G, H, K, L, M, N, P, Q, R, S, T, V, W, or Y, or WINTXXGVPTYAD (SEQ ID NO: 369), wherein X at position 5 is D, or E; X at position 6 is S, or T;

[0014] (f) HVR-H3 comprises an amino acid sequence selected from RSDGTYEGYFDY (SEQ ID NO: 43), ARGLGRAMDY (SEQ ID NO: 47), AREGDYRYYS-PLGY (SEQ ID NO: 51), ARGVGEGLFDY (SEQ ID NO: 55), AKAGSYDYFDV (SEQ ID NO: 59), ARVSMMGFAY (SEQ ID NO: 63), ARNIYYG-WGNFDY (SEQ ID NO: 67), RXDXXXXYFDY (SEQ ID NO: 203), wherein X at position 2 is S, A, F, G, I, L, M, N, R, T, V, W, or Y; X at position 4 is G, or W; X at position 5 is T, D, E, F, H, I, K, L, M, N, Q, V, W, or Y; X at position 6 is Y, D, F, H, N, R, or W; X at position 7 is E, D, G, H, K, M, N, Q, R, V, or Y; X at position 8 is G, K, R, S, or T, or ARXIYYG-WGXFDY (SEQ ID NO: 372), wherein X at position 3 is N, or M; X at position 10 is N, F, H, or Y.

[0015] In some embodiments, the present disclosure provides an anti-CD96 antibody comprising (i) a first light chain hypervariable region (HVR-L1), a second light chain hypervariable region (HVR-L2), and a third light chain hypervariable region (HVR-L3), and/or (ii) a first heavy chain hypervariable region (HVR-H1), a second heavy chain hypervariable region (HVR-H2), and a third heavy chain hypervariable region (HVR-H3), wherein:

[0016] (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO: 13;

[0017] (b) HVR-L2 comprises the amino acid sequence of SEQ ID NO: 14;

[0018] (c) HVR-L3 comprises the amino acid sequence of SEQ ID NO: 15;

[0019] (d) HVR-H1 comprises an amino acid sequence selected from SEQ ID NOs: 41, 73-106;

[0020] (e) HVR-H2 comprises an amino acid sequence selected from SEQ ID NOs: 42, 108-202;

[0021] (f) HVR-H3 comprises an amino acid sequence selected from SEQ ID NOs: 43, 204-249.

[0022] In some embodiments, the present disclosure provides an anti-CD96 antibody comprising (i) a first light chain hypervariable region (HVR-L1), a second light chain hypervariable region (HVR-L2), and a third light chain hypervariable region (HVR-L3), and/or (ii) a first heavy chain hypervariable region (HVR-H1), a second heavy chain hypervariable region (HVR-H2), and a third heavy chain hypervariable region (HVR-H3), wherein:

[0023] (a) HVR-L1 comprises the amino acid sequence of SEQ ID NO: 13;

[0024] (b) HVR-L2 comprises the amino acid sequence of SEQ ID NO: 14;

[0025] (c) HVR-L3 comprises the amino acid sequence of SEQ ID NO: 15;

[0026] (d) HVR-H1 comprises an amino acid sequence selected from SEQ ID NOs: 41, 83, 91, 92, 94, 95, 102;

[0027] (e) HVR-H2 comprises an amino acid sequence selected from SEQ ID NOs: 42, 108, 112, 113, 116, 118, 122, 125, 138, 178, 181, 190, 197;

[0028] (f) HVR-H3 comprises an amino acid sequence selected from SEQ ID NOs: 43, 208, 219, 221, 223, 227.

[0029] In some embodiments, the present disclosure provides an anti-CD96 antibody comprising (i) a first light chain hypervariable region (HVR-L1), a second light chain hypervariable region (HVR-L2), and a third light chain hypervariable region (HVR-L3), and/or (ii) a first heavy chain hypervariable region (HVR-H1), a second heavy chain hypervariable region (HVR-H2), and a third heavy chain hypervariable region (HVR-H3), wherein:

[0030] (a) HVR-L1 comprises an amino acid sequence selected from SEQ ID NOs: 37, 309-324;

[0031] (b) HVR-L2 comprises an amino acid sequence selected from SEQ ID NOs: 38, 326-334;

[0032] (c) HVR-L3 comprises an amino acid sequence selected from SEQ ID NOs: 39, 336-343;

[0033] (d) HVR-H1 comprises an amino acid sequence selected from SEQ ID NOs: 65, 345-368;

[0034] (e) HVR-H2 comprises an amino acid sequence selected from SEQ ID NOs: 66, 370-371;

[0035] (f) HVR-H3 comprises an amino acid sequence selected from SEQ ID NOs: 67, 373-376.

[0036] In some embodiments, the anti-CD96 antibody of the present disclosure comprises a light chain variable domain (V_L) amino acid sequence having at least 90% identity to a sequence selected from SEQ ID NO: 12, 16, 20, 24, 28, 32, or 36; and/or a heavy chain variable domain (V_H) amino acid sequence having at least 90% identity to a sequence selected from SEQ ID NO: 40, 44, 48, 52, 56, 60, or 64.

[0037] In some embodiments, the present disclosure provides an anti-CD96 antibody wherein the antibody comprises a light chain variable domain (V_L) amino acid sequence having at least 90% identity to a sequence of SEQ ID NO: 68, and/or a heavy chain variable domain (V_H) amino acid sequence having at least 90% identity to a sequence selected from SEQ ID NOs: 69, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 460, 461, 462, 463, or 464.